Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Concordia Healthcare Corp. Reports Results of Annual General and Special Meeting of Shareholders

TORONTO, June 27, 2014 /CNW/ - Concordia Healthcare Corp. ("Concordia") (TSX: CXR) (OTCQX: CHEHF), today announced that all of the nominees listed in the Management Information Circular of Concordia, dated May 23, 2014, for the 2014 Annual and Special Meeting of Shareholders held on June 27, 2014, in Toronto, Ontario, (the "Meeting") were elected as Directors of Concordia. The six (6) candidates nominated for election were elected by a majority of the shareholders present in person or represented by proxy at the Meeting, as follows:

  Votes For Votes Withheld
Nominees Number % Number %
Mark L. Thompson 17,429,010 99.986% 2,525 0.014%
John Huss 17,429,010 99.986% 2,525 0.014%
Ron Schmeichel 17,429,010 99.986% 2,525 0.014%
Douglas Deeth 17,429,010 99.986% 2,525 0.014%
Jordan Kupinsky 17,429,010 99.986% 2,525 0.014%
Paul Manning 17,429,035 99.986% 2,500 0.014%

In addition, at the Meeting all resolutions put to vote were passed, including the resolutions relating to the amendment to Concordia's Stock Option Plan and the adoption of Concordia's Long Term Incentive Plan.

About Concordia

Concordia is a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population. Concordia's legacy pharmaceutical business consists of Donnatal®, an adjunctive therapy in the treatment of IBS and acute enterocolitis, an ADHD-treatment drug, Kapvay® (clonidine extended release tablets), Ulesfia® (benzyl alcohol) Lotion a Head Lice Treatment, and an Asthma-related medication, Orapred ODT® (prednisolone sodium phosphate orally disintegrating tablets). Concordia's Specialty Healthcare Distribution (SHD) division (Complete Medical Homecare) distributes medical supplies targeting diabetes and related conditions. Concordia's orphan division, Pinnacle, markets Photofrin® in the United States.

Concordia operates out of facilities in Oakville, Ontario, Bridgetown, Barbados, Lenexa, Kansas (near Kansas City, Missouri), Bannockburn (near Chicago), Illinois, and Charlottesville, Virginia.

SOURCE Concordia Healthcare Corp.

For more information, please visit www.concordiarx.com or contact:

Kristen van Vogt
TMX Equicom
416-815-0700 x 244
kvanvogt@tmxequicom.com

Adam Peeler
TMX Equicom
416-815-0700 x 225
apeeler@tmxequicom.com

Copyright CNW Group 2014


Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today